Pancreatic Cancer
Conditions
Keywords
Locally advanced, Unresectable
Brief summary
The primary purpose of this trial is to define the maximum tolerated and/or recommended phase II dose of the combination of Avastin and Tarceva in patients undergoing radiation therapy for carcinoma of the pancreas. An additional primary objective is to describe the frequency and nature of grade III/IV and grade I/II toxicities associated with this regimen. Secondary objectives include describing 1-year disease-free survival and overall survival rates as well as to estimate clinical and pathologic complete response rates associated with this regimen.
Detailed description
This is a phase I/II study in which up to 18 patients will be enrolled in the phase I portion and up to an additional 26 patients in the phase II portion. Patients will be treated with Tarceva (cohort specified dose), along with fixed doses of Avastin and radiation therapy. Avastin will be given as an IV dose on days 1, 15, and 29. Tarceva will be given as a once daily by mouth. On radiation days Tarceva will be taken immediately before or after XRT. XRT will be given to a total dose of 50.4 Gy in 28 fractions, each fraction given once daily on Monday through Friday for 5.5 weeks
Interventions
DRUGAvastin
Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
DRUGTarceva
Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
RADIATIONRadiation Therapy
Radiation to the pancreas Monday through Friday for 28 treatments
Sponsors
Genentech, Inc.
Duke University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Histologically and/or cytologically confirmed adenocarcinoma of the pancreas, T1-4, N0-1, M0. Patients should have disease for which combined modality therapy is indicated. * Performance status 0-2 * Life expectancy \> 3 months * Adequate hematologic, renal, hepatic function * Calculated creatinine Cl \> 50 mL/min * Use of effective means of contraception in patients of child-bearing potential.
Exclusion criteria
* No prior therapy for pancreatic cancer * Previous treatment with bevacizumab or erlotinib * Evidence of duodenal invasion or gastric outlet obstruction * Presence of bleeding diathesis or coagulopathy * History or prior arterial thrombotic event * Conditions leading to inadequate gastrointestinal tract absorption * Poorly controlled diarrhea . * Presence of baseline proteinuria or renal dysfunction (CrCl \< 50 (Cockcroft-Gault equation) * Inadequately controlled hypertension * New York Heart Association (NYHA) Grade II or greater congestive heart failure * Clinically significant peripheral vascular disease * Presence of central nervous system or brain metastases * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study * Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0 * Pregnant or lactating females * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0 * Serious, non-healing wound, ulcer, or bone fracture * Inability to comply with study and/or follow-up procedures * Treatment for other carcinomas within the last five years, except cured non-melanoma skin cancer, curatively treated in-situ cervical cancer, or localized prostate cancer with a current PSA of \<1.0 mg/dL on 2 successive evaluations, at least 3 months apart, with the most recent evaluation no more than 4 weeks prior to entry. * Comorbid conditions that would complicate safety or compliance
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tarceva Maximum Tolerated Dose in mg | 1 yr | Tarceva maximum tolerated dose in mg |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Dose Limiting Toxicities | Within 30 days of completing radiation | — |
| One Year Overall Survival From Time of Diagnosis | 1 year | One year survival from time of diagnosis for patients who completed this regimen |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Chemoradiation Avastin 10 mg/kg intravenous infusion day 1, 15 and 29 and Tarceva 100, 125 or 150 mg once daily by mouth and Radiation Therapy Mon-Fri for 28 treatments. | 12 |
| Total | 12 |
Baseline characteristics
| Characteristic | Chemoradiation |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 2 Participants |
| Age, Categorical Between 18 and 65 years | 10 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 11 Participants |
| Region of Enrollment United States | 12 participants |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 12 / 12 |
| serious Total, serious adverse events | 0 / 12 |
Outcome results
Primary
Tarceva Maximum Tolerated Dose in mg
Tarceva maximum tolerated dose in mg
Time frame: 1 yr
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Chemoradiation | Tarceva Maximum Tolerated Dose in mg | 150 mg |
Secondary
Number of Dose Limiting Toxicities
Time frame: Within 30 days of completing radiation
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Chemoradiation | Number of Dose Limiting Toxicities | 0 Events |
Secondary
One Year Overall Survival From Time of Diagnosis
One year survival from time of diagnosis for patients who completed this regimen
Time frame: 1 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Chemoradiation | One Year Overall Survival From Time of Diagnosis | 6 participants |